8-K: Harmony Biosciences Reports Strong 2023 Growth and Pipeline Progress

Harmony Biosciences announced a 33% increase in full-year 2023 revenue, driven by strong sales of WAKIX, and provided updates on its clinical development programs.

Summary

• Harmony Biosciences reported a 31% increase in net product revenue for the fourth quarter of 2023, reaching $168.4 million, compared to $128.3 million in the same period of 2022.
• Full-year 2023 net product revenue was $582.0 million, a 33% increase from $437.9 million in 2022.
• The company's GAAP net income for the fourth quarter was $26.6 million, or $0.45 per diluted share, compared to $48.5 million, or $0.79 per diluted share, in the same quarter of the previous year.
• Non-GAAP adjusted net income for the fourth quarter was $42.8 million, or $0.73 per diluted share, compared to $61.9 million, or $1.01 per diluted share, in the same period of 2022.
• For the full year, GAAP net income was $128.9 million, or $2.13 per diluted share, compared to $181.5 million, or $2.97 per diluted share, in 2022.
• Non-GAAP adjusted net income for the full year was $188.4 million, or $3.12 per diluted share, compared to $183.5 million, or $3.00 per diluted share, in 2022.
• The company repurchased approximately 3.2 million shares of common stock for $100 million in 2023 and has $150 million remaining under its share repurchase program.
• Harmony expects full-year 2024 net product revenue to be between $700 million and $720 million.
• The average number of patients on WAKIX increased to approximately 6,150 in the fourth quarter of 2023.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and pipeline advancements, but the decrease in GAAP net income and increased operating expenses temper the overall sentiment. The company's strong cash position and share repurchase program are positive indicators.

Positives

• WAKIX continues to show strong commercial performance with a 33% increase in revenue for the full year 2023.
• The company is expanding its pipeline with the acquisition of Zynerba and the advancement of pitolisant into new indications.
• Harmony has a strong cash position of $425.6 million, providing financial flexibility.
• The company is actively repurchasing shares, indicating confidence in its future prospects.
• There is a high level of prescriber satisfaction with WAKIX, with many indicating they will continue or increase prescriptions.
• The company has strong market access coverage for WAKIX at approximately 84%.

Negatives

• GAAP net income decreased in both the fourth quarter and full year of 2023 compared to 2022.
• Operating expenses increased significantly in the fourth quarter of 2023, including one-time costs related to the Zynerba acquisition.
• Non-GAAP adjusted net income decreased in the fourth quarter of 2023 compared to the same period in 2022.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• There are risks associated with the commercialization of WAKIX and the development of new product candidates.
• The company faces competition in the pharmaceutical industry.
• The company's intellectual property position is subject to risks.
• The company's share price may be volatile and fluctuate substantially.

Future Outlook

Harmony Biosciences expects full-year 2024 net product revenue to be between $700 million and $720 million and is confident in WAKIX being a potential $1B+ opportunity in adult narcolepsy alone with the potential to contribute up to an additional $1B, if approved in other current pitolisant lifecycle management programs.

Management Comments

• Harmony delivered another year of outstanding performance in 2023, with continued strong growth for WAKIX, demonstrating its durability going into year five on the market, stated Jeffrey M. Dayno, M.D., President and Chief Executive Officer of Harmony.
• Harmony continues to be a growth story and we look forward to continued strong execution in 2024.

Industry Context

The announcement highlights Harmony's continued growth in the rare neurological disease market, particularly in narcolepsy, and its strategic expansion into new therapeutic areas. The company's focus on WAKIX and its pipeline of pitolisant-based therapies positions it as a key player in this space. The acquisition of Zynerba further diversifies its portfolio and expands its reach into other rare diseases.

Comparison to Industry Standards

• Harmony's 33% revenue growth for WAKIX in 2023 is strong compared to other pharmaceutical companies in the rare disease space, many of which experience slower growth rates.
• The company's focus on expanding the indications for pitolisant is similar to strategies employed by other companies with successful drugs, such as Vertex Pharmaceuticals with its cystic fibrosis franchise.
• The acquisition of Zynerba is a strategic move to diversify the pipeline, similar to how companies like Sarepta Therapeutics have expanded their focus beyond Duchenne muscular dystrophy.
• The company's cash position of $425.6 million is robust, providing a strong foundation for future growth and acquisitions, comparable to other well-capitalized biotech companies like BioMarin Pharmaceutical.
• The company's market access coverage of 84% for WAKIX is a strong indicator of commercial success, comparable to other established drugs in the rare disease market.

Stakeholder Impact

• Shareholders will be impacted by the company's financial performance, share repurchase program, and pipeline progress.
• Employees will be impacted by the company's growth and expansion.
• Patients will benefit from the development of new treatments for rare neurological diseases.
• Customers will be impacted by the continued availability and potential expansion of WAKIX.
• Suppliers will be impacted by the company's increased demand for products and services.
• Creditors will be impacted by the company's financial stability and debt management.

Next Steps

• The company will continue to advance its clinical development programs for pitolisant.
• The company will meet with the FDA to discuss the Idiopathic Hypersomnia development program in March 2024.
• The company will initiate the Phase 3 TEMPO study in patients with Prader-Willi syndrome in the first quarter of 2024.
• The company will report pharmacokinetic data on next-generation pitolisant formulations in the first half of 2024.
• The company will complete patient enrollment in the Phase 3 RECONNECT trial for Fragile X syndrome in the first quarter of 2025.
• The company will continue to evaluate business development opportunities to build out its pipeline.

Key Dates

Keywords

WAKIX, pitolisant, narcolepsy, idiopathic hypersomnia, Prader-Willi syndrome, Fragile X syndrome, Myotonic Dystrophy, ZYN002, HBS-102, revenue, clinical trials, FDA, orphan drug designation, pharmaceuticals